Key Takeaways NEOG posted Q2 EPS of 10 cents and revenues of $224.7M, both beating estimates, as the stock surged 31.6%.Neogen's 2.9% core revenue growth countered sales declines tied to divestitures and discontinued products.NEOG raised fiscal 2026 guidance, forecasting $845M-$855M in revenues and about $175M in adjusted EBITDA.Neogen Corporation (NEOG) reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 10 cents, which topped the Zacks Consensus Estimate by 42.86%. However, the bottom ...

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!In October I concluded that Neogen ( NEOG ) , itself being a food safety play, was still not a safety play itself, at least for investors. Following a well-documented and incredibly value-destruct ...

评级与目标价调整 - 古根海姆将Neogen评级上调至“买入”并设定新目标价12美元 较此前目标价8美元上调50% [1][5] - 评级上调时公司股价为9.71美元 新目标价隐含约23.6%的上涨空间 [1] 财务业绩表现 - 公司第二财季营收为2.247亿美元 同比下降近3% [2][3] - 非GAAP净利润为2260万美元 同比略有下降 [2][3] - 业绩超出市场预期 分析师此前预期营收仅略高于2.08亿美元 非GAAP每股收益仅为0.03美元 [2] 股价与市场反应 - 财报发布后公司股价飙升超过31% 上涨2.33美元至9.71美元 涨幅精确为31.57% [2][3][5] - 当日股价在9.12美元至10.24美元之间波动 过去52周股价区间为3.87美元至12.98美元 [4] - 公司当前市值约为21.1亿美元 当日成交量为2268万股 [4] 业绩驱动因素与解释 - 营收同比下降主要归因于资产剥离及产品线停产 [3][5] - 股价大幅上涨源于公司业绩超越市场预测 获得了投资者的积极回应 [3][5]

We recently published Wall Street Can’t Keep up With These 10 Stocks on Fire. Neogen Corporation (NASDAQ:NEOG) was one of the top performers on Thursday. Neogen climbed to a 10-month high on Thursday, as investors cheered its strong earnings performance in the recently concluded quarter, alongside a higher revenue guidance for the fiscal year 2026. At intra-day trading, the stock jumped to as high as $10.24—a level it last touched in March 2025—before paring gains to finish the day just up by 31.57 perce ...

核心财务表现 - 截至2025年11月的季度，公司营收为2.2469亿美元，同比下降2.8% [1] - 季度每股收益为0.10美元，低于去年同期的0.11美元 [1] - 季度营收超出Zacks一致预期2.0974亿美元，带来7.13%的正向意外 [1] - 季度每股收益为0.10美元，未达到0.07美元的Zacks一致预期，未带来每股收益惊喜 [1] 股价与市场评级 - 过去一个月，公司股价回报率为+5.7%，同期Zacks S&P 500综合指数回报率为+0.9% [3] - 公司股票目前Zacks评级为4（卖出），表明其近期可能跑输大市 [3] 分业务板块收入表现 - **动物安全业务**总收入为5914万美元，同比下降11.8%，但高于三位分析师平均预期的5656万美元 [4] - **食品安全业务**总收入为1.6555亿美元，同比微增0.8%，远超三位分析师平均预期的1.5319亿美元 [4] 食品安全业务细分收入 - **指示剂测试、培养基及其他**收入为8611万美元，同比增长3.4%，高于两位分析师平均预期的7636万美元 [4] - **天然毒素与过敏原**收入为2044万美元，同比微降0.3%，高于两位分析师平均预期的1910万美元 [4] - **细菌与常规卫生**收入为4492万美元，同比增长5.6%，高于两位分析师平均预期的3928万美元 [4] - **基因组学服务**收入为626万美元，低于两位分析师平均预期的1393万美元 [4] - **生物安全产品**收入为457万美元，低于两位分析师平均预期的874万美元 [4] 动物安全业务细分收入 - **生命科学**收入为145万美元，同比下降11%，低于两位分析师平均预期的160万美元 [4] - **兽医器械与耗材**收入为1368万美元，同比下降20.8%，低于两位分析师平均预期的1568万美元 [4] - **动物护理及其他**收入为889万美元，同比下降9%，低于两位分析师平均预期的1041万美元 [4] - **基因组学服务**收入为1718万美元，远超两位分析师平均预期的483万美元 [4] - **生物安全产品**收入为1793万美元，略低于两位分析师平均预期的1870万美元 [4]

核心财务表现 - 第二季度每股收益为0.10美元，超出市场预期的0.07美元 [1][6] - 第二季度营收约为2.247亿美元，超出市场预期的2.084亿美元 [2][6] - 公司已上调其全年营收展望 [2] 业务运营与战略 - 公司专注于提供食品和动物安全解决方案 [1] - 公司正处于战略转型的早期阶段，旨在稳定和加强其核心业务 [3][6] - 尽管面临宏观经济挑战，但核心收入增长已实现显著的连续改善 [3] 市场与估值指标 - 公司市盈率（P/S）为2.41，意味着投资者为每1美元销售额支付2.41美元 [4][6] - 企业价值与销售额比率（EV/Sales）约为2.24 [4] - 企业价值与营运现金流比率（EV/OCF）约为30.75 [5] 财务健康状况 - 流动比率约为3.91，显示出良好的短期财务健康状况 [4][6] - 强劲的业绩表现是推动投资者信心的关键因素，并带动了股价显著上涨 [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) | Michigan 38-2367843 | | | | --- | --- | --- | | (State or other jurisdiction of (IRS Employer | | | | incorporation or organization) Identification Number) | | | | 620 Lesher Place | | | | Lansing, Michigan 48912 | | | | (Address of principal executive offices, including ...

Neogen Corp. (NASDAQ:NEOG) stock rose after the company reported better-than-expected second-quarter financial results.Second-quarter 2026 adjusted earnings came in at 10 cents per share, beating the consensus of 6 cents.Sales were $224.69 million, down 2.8% year over year, and exceeded the consensus of $207.85 million. Core revenue increased by 2.9%.“As we look to the second half of the fiscal year, we remain highly focused on the integration of Petrifilm and optimization of sample collection manufacturing ...

Shares of a small cap food and animal safety diagnostics provider are skyrocketing to start the day.Neogen Corporation (NEOG) soared as high as 33.74% in the last 24 hours, reaching a current price of $9.62 and a $2.09 billion market cap. The move happened as the firm reported strong quarterly results, beating earnings per share expectations with $0.10 against a forecast of $0.03, while revenue hit $224.7 million reflecting 2.9% core growth.The company says its food safety segment continues to benefit from ...

Neogen beat earnings estimates, raised its full-year revenue outlook, and has now posted back-to-back post-earnings stock spikes. ...